Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.

Zha X, Diaz R, Franco JJ, Sanchez VF, Fasoli E, Barletta G, Carvajal A, Bansal V.

Molecules. 2013 Jul 26;18(8):8945-58. doi: 10.3390/molecules18088945.

2.

The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.

Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW.

J Immunol Methods. 1997 Apr 11;203(1):55-65.

PMID:
9134030
3.
6.
7.

Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.

Towle MJ, Lee A, Maduakor EC, Schwartz CE, Bridges AJ, Littlefield BA.

Cancer Res. 1993 Jun 1;53(11):2553-9.

8.

Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta.

Shireman PK, McCarthy WJ, Pearce WH, Shively VP, Cipollone M, Kwaan HC.

J Vasc Surg. 1997 Jan;25(1):157-64.

9.

Identification of a novel inhibitor of urokinase-type plasminogen activator.

Zhu M, Gokhale VM, Szabo L, Munoz RM, Baek H, Bashyam S, Hurley LH, Von Hoff DD, Han H.

Mol Cancer Ther. 2007 Apr;6(4):1348-56.

10.

Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.

Schmitt M, Wilhelm O, Jänicke F, Magdolen V, Reuning U, Ohi H, Moniwa N, Kobayashi H, Weidle U, Graeff H.

J Obstet Gynaecol (Tokyo 1995). 1995 Apr;21(2):151-65. Review.

PMID:
8556577
11.
12.

Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.

Jankun J, Skrzypczak-Jankun E.

Cancer Biochem Biophys. 1999 Jul;17(1-2):109-23.

PMID:
10738907
13.

Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.

Katz BA, Mackman R, Luong C, Radika K, Martelli A, Sprengeler PA, Wang J, Chan H, Wong L.

Chem Biol. 2000 Apr;7(4):299-312.

14.

Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.

Jankun J, Keck RW, Skrzypczak-Jankun E, Swiercz R.

Cancer Res. 1997 Feb 15;57(4):559-63. Erratum in: Cancer Res 1998 Jan 1;58(1):179.

16.

Pro-urokinase-type plasminogen activator is a substrate for hepsin.

Moran P, Li W, Fan B, Vij R, Eigenbrot C, Kirchhofer D.

J Biol Chem. 2006 Oct 13;281(41):30439-46. Epub 2006 Aug 14.

17.

Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.

Muehlenweg B, Sperl S, Magdolen V, Schmitt M, Harbeck N.

Expert Opin Biol Ther. 2001 Jul;1(4):683-91. Review.

PMID:
11727504
18.
19.

Regulated localization confers multiple functions on the protease urokinase plasminogen activator.

Wells JM, Strickland S.

J Cell Physiol. 1997 May;171(2):217-25.

PMID:
9130470
20.

Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.

España F, Estellés A, Fernández PJ, Gilabert J, Sánchez-Cuenca J, Griffin JH.

Thromb Haemost. 1993 Dec 20;70(6):989-94.

PMID:
8165623

Supplemental Content

Support Center